XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2

Segments (Tables)

9 Months Ended

Sep. 30, 2021

Summary of Segment Profit

a. Segment information:

		Three months ended September 30,
		2021
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,875			$	1,220			$	530
Gross profit			967				714				296
R&D expenses			146				55				16
S&M expenses			250				204				102
G&A expenses			121				64				29
Other income			(7	)			(2	)			(2	)
Segment profit		$	458			$	394			$	152

§ Represents an amount less than $1 million.

		Three months ended September 30,
		2020
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,017			$	1,116			$	529
Gross profit			1,056				637				275
R&D expenses			155				60				17
S&M expenses			250				200				101
G&A expenses			97				66				33
Other income			(5	)			(1	)			(1	)
Segment profit		$	560			$	312			$	125

		Nine months ended September 30,
		2021
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	5,807			$	3,618			$	1,505
Gross profit			3,081				2,063				826
R&D expenses			467				184				51
S&M expenses			734				628				303
G&A expenses			338				180				79
Other income			(14	)			(3	)			(5	)
Segment profit		$	1,556			$	1,074			$	398

		Nine months ended September 30,
		2020
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	6,146			$	3,520			$	1,582
Gross profit			3,208				2,009				828
R&D expenses			455				180				51
S&M expenses			755				590				312
G&A expenses			325				184				96
Other income			(9	)			(3	)			(10	)
Segment profit		$	1,682			$	1,058			$	378

Schedule Of Consolidated Income Before Income Tax

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended September 30, 2021 and 2020:

.		Three months ended								Nine months ended
		September 30,								September 30,
		2021				2020				2021				2020
		(U.S. $ in millions)								(U.S. $ in millions)
North America profit		$	458			$	560			$	1,556			$	1,682
Europe profit			394				312				1,074				1,058
International Markets profit			152				125				398				378
Total reportable segments profit			1,004				997				3,028				3,118
Profit of other activities			38				28				125				130
Total segments profit			1,042				1,025				3,153				3,248
Amounts not allocated to segments:
Amortization			199				251				613				758
Other assets impairments, restructuring and other items			62				(98	)			227				404
Goodwill impairment			—				4,628				—				4,628
Intangible asset impairments			21				509				295				1,278
Legal settlements and loss contingencies			3				21				113				10
Other unallocated amounts			134				55				266				148
Consolidated operating income (loss)			623				(4,342	)			1,638				(3,978	)
Financial expenses, net			241				117				805				565
Consolidated income (loss) before income taxes		$	382			$	(4,459	)		$	833			$	(4,543	)

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three and nine months ended September 30, 2021 and 2020:

North America		Three months ended September 30,
		2021				2020
		(U.S. $ in millions)
Generic products		$	859			$	928
AJOVY			46				35
AUSTEDO			201				168
BENDEKA®/TREANDA®			95				105
COPAXONE			133				236
ProAir®*			31				50
Anda			363				341
Other			146				155
Total		$	1,875			$	2,017

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

North America		Nine months ended September 30,
		2021				2020
		(U.S. $ in millions)
Generic products		$	2,864			$	2,804
AJOVY			123				98
AUSTEDO			520				451
BENDEKA/TREANDA			292				313
COPAXONE			448				671
ProAir*			140				175
Anda			968				1,141
Other			451				493
Total		$	5,807			$	6,146

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

Europe		Three months ended September 30,
		2021				2020
		(U.S. $ in millions)
Generic products		$	895			$	824
AJOVY			23				8
COPAXONE			95				101
Respiratory products			85				77
Other			122				106
Total		$	1,220			$	1,116

Europe		Nine months ended September 30,
		2021				2020
		(U.S. $ in millions)
Generic products		$	2,637			$	2,593
AJOVY			58				17
COPAXONE			296				294
Respiratory products			263				263
Other			364				352
Total		$	3,618			$	3,520

International markets		Three months ended September 30,
		2021				2020
		(U.S. $ in millions)
Generic products		$	412			$	429
AJOVY			39				16
COPAXONE			10				14
Other			69				71
Total		$	530			$	529

International markets		Nine months ended September 30,
		2021				2020
		(U.S. $ in millions)
Generic products		$	1,211			$	1,304
AJOVY			46				17
COPAXONE			29				38
Other			219				224
Total		$	1,505			$	1,582

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration